Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105117 | 0.84 | GAK (0.51) | POLBPDE4DMAPTPDE4APDE4B | |
| SCHEMBL1157766 | 0.82 | RAB9A (0.51) | POLBRAB9APDE4DPDE4APDE4B | |
| SCHEMBL1157431 | 0.81 | POLB (0.55) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157366 | 0.80 | POLB (0.56) | POLBPDE4DMAPTPDE4AMAPK1 | |
| SCHEMBL1157747 | 0.78 | QRFPR (0.61) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157849 | 0.78 | PDE4D (0.53) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL1157857 | 0.78 | POLB (0.54) | POLBPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6801941 | 0.78 | POLB (0.49) | POLBPDE4DPDE4AGRM4PDE4B | |
| SCHEMBL1157796 | 0.77 | PDE4D (0.55) | POLBPDE4DLMNAPDE4APDE4B | |
| SCHEMBL1157875 | 0.77 | PDE4D (0.64) | POLBPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2011-02-24 | — | — | US | disclosed |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-7205320-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A | 2007-04-05 | — | — | US | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | SCHUMACHER RICHARD A (US) | 2004-11-18 | — | — | US | disclosed |
| US-6699890-B2 | N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES | MEMORY PHARMACEUTICALS CORP. | 2004-03-02 | — | — | US | disclosed |
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151566-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | POLB 1326/4885HCRTR1 4023/4885RAB9A 1706/4885 |
| US-20040230072-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3A | POLB 1326/4885HCRTR1 4023/4885RAB9A 1706/4885 |
| US-20110046146-A9 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | POLB 1838/4885HCRTR1 3755/4885RAB9A 2026/4885 |
| US-20070078139-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | POLB 1838/4885HCRTR1 3755/4885RAB9A 2026/4885 |
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | POLB 1404/4885HCRTR1 3993/4885RAB9A 2356/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | POLB 1404/4885HCRTR1 3993/4885RAB9A 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.